206. Fragile X syndrome Clinical trials / Disease details
Clinical trials : 108 / Drugs : 91 - (DrugBank : 36) / Drug target genes : 52 - Drug target pathways : 77
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT02680379 (ClinicalTrials.gov) | March 2016 | 25/1/2016 | Combined Treatment of Minocycline and Lovastatin to Treat Individuals With Fragile X Syndrome | A Pilot Study Exploring the Safety and Synergistic Effect of a Minocycline/Lovastatin Combined Treatment on the Behavior of Individuals With Fragile X Syndrome; Validation of New Biochemical and Neurophysiological Markers (LovaMiX) | Fragile X Syndrome | Drug: Minocycline, then Minocycline/Lovastatin;Drug: Lovastatin, then Minocycline/Lovastatin | Université de Sherbrooke | FRAXA Research Foundation | Completed | 8 Years | 45 Years | All | 22 | Phase 2 | Canada |